Compare Organon & Co. Common Stock (OGN) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs TeraWulf Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while TeraWulf Inc trades at $11.15 (market cap $6.59B). The key difference: TeraWulf Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and TeraWulf Inc for 18 Days on average.
| OGN | WULF | |
|---|---|---|
Market Cap | $3.62B | $6.59B |
Volume | 2,892,999 | 33,904,053 |
Sector | Health | Financials |
52-Week High | $13.81 | $28.98 |
52-Week Low | $5.70 | $10.99 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $11.04B | $9.21B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
WULF trades at $13.21, down 1.2% on the day, with a bearish technical signal from moving averages. The company reported a net loss of -$661.42M in 2025, with a negative net income margin of -1,179.94%, though it maintains a high gross profit margin of 69.26%. Recent news highlights its pivot to AI data centers, with shares experiencing volatility amid sector-wide momentum.
Analyst consensus is strongly bullish with a $34.92 price target, but high valuation ratios and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI infrastructure strategy amid substantial financial leverage and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
